Comparing CAR T-Cell Therapies in Lymphoma – Medscape
Medscape |
Comparing CAR T-Cell Therapies in Lymphoma
Medscape Dr Jacobson: We are really talking about the anti–CD19-directed CAR T cells and the three products that are furthest along in development: tisagenlecleucel (Novartis), axicabtagene ciloleucel (Kite), and JCAR017 (Juno). What is pretty remarkable is … |
